0001622667-20-000001.txt : 20200831 0001622667-20-000001.hdr.sgml : 20200831 20200831140331 ACCESSION NUMBER: 0001622667-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200831 DATE AS OF CHANGE: 20200831 EFFECTIVENESS DATE: 20200831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AEON Biopharma, Inc. CENTRAL INDEX KEY: 0001622667 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454777018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-374494 FILM NUMBER: 201150994 BUSINESS ADDRESS: STREET 1: 4040 MACARTHUR BOULEVARD STREET 2: SUITE 310 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 BUSINESS PHONE: 949-284-4555 MAIL ADDRESS: STREET 1: 4040 MACARTHUR BOULEVARD STREET 2: SUITE 310 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 FORMER COMPANY: FORMER CONFORMED NAME: Alphaeon Corp DATE OF NAME CHANGE: 20141017 D 1 primary_doc.xml X0708 D LIVE 0001622667 AEON Biopharma, Inc. 4040 MACARTHUR BOULEVARD SUITE 260 NEWPORT BEACH CA CALIFORNIA 92660 (949) 260-1700 DELAWARE Alphaeon Corp Corporation true Simone Blank 4040 MacArthur Blvd., Suite 260 Newport Beach CA CALIFORNIA 92660 Director Jost Fischer 4040 MacArthur Blvd., Suite 260 Newport Beach CA CALIFORNIA 92660 Director Robert Grant 4040 MacArthur Blvd., Suite 260 Newport Beach CA CALIFORNIA 92660 Director Vikram Malik 4040 MacArthur Blvd., Suite 260 Newport Beach CA CALIFORNIA 92660 Director Darren O'Brien 4040 MacArthur Blvd., Suite 260 Newport Beach CA CALIFORNIA 92660 Director Richard Taketa 4040 MacArthur Blvd., Suite 260 Newport Beach CA CALIFORNIA 92660 Director Marc Forth 4040 MacArthur Blvd., Suite 260 Newport Beach CA CALIFORNIA 92660 Executive Officer Chris Carr 4040 MacArthur Blvd., Suite 260 Newport Beach CA CALIFORNIA 92660 Executive Officer Scott Akamine 4040 MacArthur Blvd., Suite 260 Newport Beach CA CALIFORNIA 92660 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2020-08-25 false true true true true The subordinated convertible promissory notes may be repaid in cash or converted into an indeterminate number of shares of common stock. false 0 25000000 25000000 0 The Note Purchase Agreement dated August 25, 2020, provides for the sale and issuance of subordinated convertible promissory notes in the aggregate principal amount of $25,000,000, of which $15,000,000 will be issued on or about September 18, 2020. false 1 0 0 0 false AEON Biopharma, Inc. /s/ Scott Akamine Scott Akamine General Counsel and Secretary 2020-08-31